select a format

Single User License
USD 250 INR 16035
Site License
USD 500 INR 32070
Corporate User License
USD 750 INR 48105

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Zymeworks Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Zymeworks Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH186157D
  • |
  • Pages: 47
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Zymeworks Inc (Zymeworks) is a biotherapeutics company that develops antibody and protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases. The company also develops technologies in the area of biologics drug discovery and optimization. Its zymeCAD is a protein engineering technology platform that develops antibody and antibody alternative products. Zymeworks' pipeline products include ZW25 and ZW33. The company's conjugation platform is a novel protein site-specific conjugation technologies, which is compatible with various small molecule therapeutics. It serves pharmaceutical and chemical markets. The company has presence in Canada and the US. Zymeworks is headquartered in Vancouver, British Columbia, Canada.

Zymeworks Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Zymeworks Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Zymeworks Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Zymeworks Raises USD61.5 Million in Series A Financing 12

Zymeworks Raises USD4 Million in Venture Financing 14

Zymeworks Raises US$11 Million In Venture Financing 14

Zymeworks Secures Additional US$4 Million In Venture Financing 15

Zymeworks Secures US$8.1 Million In Financing 16

Partnerships 17

ImClone Systems Enters Licensing Agreement with Zymeworks 17

Zymeworks Enters into Research Agreement with University of Victoria and BC Cancer Agency 18

Applied BioMath Extends Partnership with Zymeworks 19

Zymeworks Enters into Agreement with Kairos Therapeutics 20

ProBioGen Enters into Agreement with Zymeworks 20

Zymeworks Enters into Research Agreement with University of California, Los Angeles 21

National Research Council Enters into Co-Development Agreement with Zymeworks for Cancer 22

Licensing Agreements 23

Zymeworks Enters into Licensing Agreement with Daiichi Sankyo 23

Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 24

Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 25

Zymeworks Enters into Licensing Agreement with Selexis 26

Celgene Enters into Licensing Agreement with Zymeworks for Bi-Specific Antibody 26

Zymeworks Extends Licensing Agreement with Merck 27

Eli Lilly Enters into Licensing Agreement with Zymeworks 28

Zymeworks Enters into Licensing Agreement with Merck 29

Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 30

Zymeworks Enters into Licensing Agreement with Innovative Targeting Solutions 31

Equity Offering 32

Zymeworks Raises USD58.5 Million in IPO 32

Zymeworks Raises USD1.8 Million in Private Placement of Shares 34

Zymeworks Raises USD8.6 Million in Private Placement of Shares 34

Zymeworks Completes Private Placement of Shares for USD17.3 Million 35

Acquisition 36

Zymeworks Acquires Remaining 80.01% Stake in Kairos Therapeutics for USD24.8 Million 36

Zymeworks Acquires 19.99% Stake in Kairos Therapeutics for USD3.6 Million 37

Zymeworks Inc-Key Competitors 38

Key Employees 39

Locations And Subsidiaries 40

Head Office 40

Other Locations & Subsidiaries 40

Recent Developments 41

Financial Announcements 41

May 15, 2017: Zymeworks Reports First Quarter 2017 Financial Results 41

Corporate Communications 42

Feb 14, 2017: Zymeworks Appoints Dr. Kenneth Hillan and Hollings Renton to its Board of Directors 42

Nov 22, 2016: Zymeworks Announces the Addition of Lota S. Zoth to Its Board of Directors 43

Apr 26, 2016: Zymeworks Names Diana Hausman, M.D. Chief Medical Officer 44

Product News 45

Jan 19, 2016: Zymeworks Announces the Successful Achievement of a Milestone with Lilly in Bi-Specific Antibody Therapeutics Collaboration 45

Jan 05, 2017: Zymeworks Announces the Successful Achievement of a Research Milestone with Lilly in Bispecific Antibody Collaboration 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47

List of Figures

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Zymeworks Inc, Pharmaceuticals & Healthcare, Key Facts 1

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Zymeworks Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Zymeworks Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Zymeworks Raises USD61.5 Million in Series A Financing 12

Zymeworks Raises USD4 Million in Venture Financing 14

Zymeworks Raises US$11 Million In Venture Financing 14

Zymeworks Secures Additional US$4 Million In Venture Financing 15

Zymeworks Secures US$8.1 Million In Financing 16

ImClone Systems Enters Licensing Agreement with Zymeworks 17

Zymeworks Enters into Research Agreement with University of Victoria and BC Cancer Agency 18

Applied BioMath Extends Partnership with Zymeworks 19

Zymeworks Enters into Agreement with Kairos Therapeutics 20

ProBioGen Enters into Agreement with Zymeworks 20

Zymeworks Enters into Research Agreement with University of California, Los Angeles 21

National Research Council Enters into Co-Development Agreement with Zymeworks for Cancer 22

Zymeworks Enters into Licensing Agreement with Daiichi Sankyo 23

Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 24

Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 25

Zymeworks Enters into Licensing Agreement with Selexis 26

Celgene Enters into Licensing Agreement with Zymeworks for Bi-Specific Antibody 26

Zymeworks Extends Licensing Agreement with Merck 27

Eli Lilly Enters into Licensing Agreement with Zymeworks 28

Zymeworks Enters into Licensing Agreement with Merck 29

Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 30

Zymeworks Enters into Licensing Agreement with Innovative Targeting Solutions 31

Zymeworks Raises USD58.5 Million in IPO 32

Zymeworks Raises USD1.8 Million in Private Placement of Shares 34

Zymeworks Raises USD8.6 Million in Private Placement of Shares 34

Zymeworks Completes Private Placement of Shares for USD17.3 Million 35

Zymeworks Acquires Remaining 80.01% Stake in Kairos Therapeutics for USD24.8 Million 36

Zymeworks Acquires 19.99% Stake in Kairos Therapeutics for USD3.6 Million 37

Zymeworks Inc, Key Competitors 38

Zymeworks Inc, Key Employees 39

Zymeworks Inc, Other Locations 40

Zymeworks Inc, Subsidiaries 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Zymeworks Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com